A Nobel Prize Winner’s Startup Raised $350 Million. Now It Can’t Fund Its Cancer Programs
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Original Source
Read the full article at Inc →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.